Remed Co

Remed Co EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Remed Co (302550.KQ) as of Nov 19, 2026 is 134.11. In the previous year, EV/EBITDA (Enterprise Value to EBITDA) was 51.03 — a change of 162.81% (higher).

EV/EBITDA

134.11

YoY

162.81%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Remed Co is 2025 134.11 . EV/EBITDA (Enterprise Value to EBITDA) of Remed Co was 2024 51.03 . It decreases by 162.81% higher compared to the previous year.

The Remed Co EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2017
222.21 KRW
Jan 1, 2018
-125.81 KRW
Jan 1, 2019
18.72 KRW
Jan 1, 2020
37.33 KRW
Jan 1, 2021
60.20 KRW
Jan 1, 2023
58.96 KRW
Jan 1, 2024
51.03 KRW
Jan 1, 2025
134.11 KRW
The Remed Co EV/EBITDA history
YEAREV/EBITDAYoY
134.11+162.81%
51.03-13.44%
58.96-2.06%
60.20+61.24%
37.33+99.45%
18.72-114.88%
-125.81-156.62%
222.21—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Remed Co Stock analysis

What does Remed Co do? REMED Co., Ltd. generates revenue through the manufacturing and sale of medical equipment, including transcranial magnetic stimulation (TMS) therapy machines, pain therapy machines, and biosignal and monitoring machines. Pain therapy machines encompass electromagnetic stimulation machines, extracorporeal shockwave therapy machines, and high intensity laser therapy machines. Biosignal and monitoring machines include patient monitors, fetal monitors, and electrocardiogram (ECG/EKG) machines. The company distributes these products domestically and internationally, targeting healthcare providers and medical facilities that require specialized therapeutic and monitoring solutions. The firm's product portfolio focuses on advanced medical devices for neurological and pain management, as well as patient monitoring. Transcranial magnetic stimulation (TMS) therapy machines are used for neurological treatments, while pain therapy machines address chronic pain conditions. Biosignal and monitoring machines support critical patient care, with electrocardiogram (ECG/EKG) machines being a key component. These products are sold to hospitals, clinics, and medical centers across domestic and overseas markets. REMED Co., Ltd. serves healthcare institutions that require specialized equipment for diagnosis, treatment, and monitoring. The domestic market includes hospitals and clinics in Daejeon, while overseas markets extend to international healthcare providers. The company’s revenue streams are derived from direct sales of its medical equipment, with no mention of additional services or licensing agreements in the business description. Remed Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Remed Co stock

EV/EBITDA (Enterprise Value to EBITDA) of Remed Co is 134.11 in 2025.

EV/EBITDA (Enterprise Value to EBITDA) of Remed Co changed from 51.03 to 134.11, representing a 162.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Remed Co since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Remed Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Remed Co

All Key Metrics — Remed Co